SCHEMBL15210587

SCHEMBL15210587

COc1ccc(C(N)=O)cc1-c1cc2nccc(-c3ccc4[nH]cnc4c3)c2o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.44
CAMKK2 Q96RR4 2/20 0.39
TERT O14746 1/20 0.39
CHUK O15111 1/20 0.39
INSR P06213 1/20 0.39
MAPK8 P45983 1/20 0.39
CYP1A1 P04798 1/20 0.39
CYP1B1 Q16678 1/20 0.39
FYN P06241 2/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CHEK2 O96017 4/20 0.36
QPCT Q16769 1/20 0.36
CHEK1 O14757 1/20 0.36
NSD2 O96028 1/20 0.36
MKNK1 Q9BUB5 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
FLT3 P36888 1/20 0.35
PIK3CG P48736 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15210449 0.89 AR (0.41) ARCAMKK2TERTCHUKINSR
SCHEMBL15210384 0.86 MAPK1 (0.43) ARCAMKK2CHUKINSRMAPK8
SCHEMBL15210357 0.83 TERT (0.39) TERTCYP1A1CYP1B1QPCTADORA2A
SCHEMBL15210343 0.81 GAA (0.41) ARCAMKK2CHUKINSRMAPK8
SCHEMBL15210434 0.81 CAMKK2 (0.39) ARCAMKK2CHUKINSRMAPK8
SCHEMBL15210433 0.81 CDK4 (0.40) TERTCYP1A1CYP1B1CHEK1
SCHEMBL15210462 0.79 CAMKK2 (0.42) CAMKK2CHUKINSRMAPK8FYN
SCHEMBL722573 0.79 TERT (0.46) TERTCYP1A1CYP1B1QPCT
SCHEMBL15210505 0.79 CAMKK2 (0.38) ARCAMKK2CHUKINSRMAPK8
SCHEMBL15212570 0.78 MKNK1 (0.42) ARCAMKK2CHUKINSRMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP claimed
EP-2817313-A1 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2014-12-31 EP claimed
WO-2013124025-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO claimed
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP disclosed
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP disclosed
US-20150038527-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-02-05 US disclosed
US-20150038527-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-02-05 US disclosed
EP-2817313-A1 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2014-12-31 EP disclosed
WO-2013124025-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO disclosed
WO-2013124025-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038527-A1 FUROPYRIDINE DERIVATIVES SYK, LYN, BTK AR 2855/4885CAMKK2 2444/4885TERT 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.